Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2020-06-01

Original market date: See footnote 1

2020-06-01

Product name:

AVSOLA

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02496933

Product Monograph/Veterinary Labelling:

Date: 2020-03-12 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

AMGEN CANADA INC
6775 Financial Drive, Suite 100
Mississauga
Ontario
Canada  L5N 0A4

Class: 

Human

Dosage form(s):

Powder For Solution

Route(s) of administration:

Intravenous

Number of active ingredient(s):

1

Schedule(s):

Schedule D,  Prescription  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

92:36.00   DISEASE-MODIFYING ANTIRHEUMATIC AGENTS

Anatomical Therapeutic Chemical (ATC): See footnote 4

L04AB02  INFLIXIMAB

Active ingredient group (AIG) number:See footnote 5

0144162001

List of active ingredient(s)
Active ingredient(s) Strength
INFLIXIMAB 100 MG / VIAL

Application information

Related information

Contact us

Version 3.7.4
Date modified: